secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001641172-25-000689
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate reports FY 2024 net loss $15.5M; cash runway extended to Q4 2025, NDA for CTx-1301 targeted mid-2025
--------------------------------------------------------------------------------

- Cash and equivalents $12.2M (vs $52k Dec 2023); working capital improved to $7.5M from -$9.6M.
- Net loss narrowed to $15.5M from $23.5M in 2023; R&D expenses fell to $9.4M from $15.5M.
- Pre-NDA FDA meeting scheduled April 2, 2025; NDA submission for CTx-1301 targeted mid-2025.
- Phase 3 pediatric safety data showed no serious TEAEs across nine clinical trials.
- Raised $17.5M in capital in 2024 via public offering, warrant inducement, and promissory note.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000164117225000689/0001641172-25-000689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000164117225000689/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer